Efficacy and safety of liposomal irinotecan plus nimotuzumab in immune checkpoint inhibitor-refractory recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase II trial.
- DOI
- 10.1016/j.eclinm.2026.104170
- Published
- 2026-08-31
- Container
- EClinicalMedicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.eclinm.2026.104170,
title = {Efficacy and safety of liposomal irinotecan plus nimotuzumab in immune checkpoint inhibitor-refractory recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase II trial.},
author = {He S and Bei WX and Lu N and Zhao ZY and Ye Y and Chen C and Tang L and Liu L and Lv S and Xiang YQ and Wang L.},
year = {2026},
journal = {EClinicalMedicine},
doi = {10.1016/j.eclinm.2026.104170},
url = {https://doi.org/10.1016/j.eclinm.2026.104170}
}RIS
TY - JOUR TI - Efficacy and safety of liposomal irinotecan plus nimotuzumab in immune checkpoint inhibitor-refractory recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase II trial. AU - He S AU - Bei WX AU - Lu N AU - Zhao ZY AU - Ye Y AU - Chen C AU - Tang L AU - Liu L AU - Lv S AU - Xiang YQ AU - Wang L. PY - 2026 JO - EClinicalMedicine DO - 10.1016/j.eclinm.2026.104170 UR - https://doi.org/10.1016/j.eclinm.2026.104170 ER -
APA
S, H., WX, B., N, L., ZY, Z., Y, Y., C, C., L, T., L, L., S, L., YQ, X., & L., W. (2026). Efficacy and safety of liposomal irinotecan plus nimotuzumab in immune checkpoint inhibitor-refractory recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase II trial.. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2026.104170
Source records
- europe-pmc · retrieved 2026-09-27T06:00:01.137Z
- doaj · retrieved 2026-09-27T06:00:01.154Z